Potent and specific inhibitor of phosphoinositide 3-kinasep110α isoform (IC50=0.0020µM). p110β isoform (IC50=0.016µM)p110γ isoform (IC50=0.66µM)C2β isoform (IC50=0.22µM). Inhibits proliferation of A375 melanoma cells (IC50=0.58µM). Inhibits proliferation of U87MG human glioblastoma cells (IC50=1.10.µM).Inhibits proliferation of A2780 human ovarian cells (IC50=0.27µM).
Product Details
| Alternative Name: | 3-[4-(4-Morpholinyl)thieno[3,2-d]pyrimidin-2-yl]-phenol |
| |
| Formula: | C16H15N3O2S |
| |
| MW: | 313.4 |
| |
| CAS: | 371943-05-4 |
| |
| Purity: | ≥99% (HPLC) |
| |
| Appearance: | White to off-white solid. |
| |
| Solubility: | Soluble in DMSO or dioxane. |
| |
| Shipping: | Ambient Temperature |
| |
| Long Term Storage: | -20°C |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
Product Literature References
The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin -4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer: A.J. Folkes; J. Med. Chem.
51, 5522 (2008),
Abstract;
Synthesis and biological evaluation of 4-morpholino-2-phenylquinazolines and related derivatives as novel PI3 kinase p110alpha inhibitors: M. Hayakawa, et al.; Bioorg. Med. Chem.
14, 6847 (2006),
Abstract;
